REGU-MATE SOLUTION
Oral Progestin
Regu-Mate (altrenogest) Solution
0.22% is indicated for the suppression of estrus in mares. Suppression of estrus allows for
a predictable occurrence of estrus following drug withdrawal. This facilitates
the attainment of regular cyclicity during the transition from winter anestrus
to the physiological breeding season. Suppression of estrus will also facilitate
management of prolonged estrus conditions. Suppression of estrus may be used to
facilitate scheduled breeding during the physiological breeding season.
Regu-Mate Solution
0.22% produces a progestational effect in mares. It contains the active synthetic progestin - altrenogest.
Active Ingredients: Each ml of Regu-Mate (altrenogest)
Solution 0.22% contains 2.2 mg of altrenogest in an oil solution.
Dosage and Administration:
While wearing protective gloves, administer
orally at the rate of 1 mL per 110 pounds body weight (0.044 mg/kg) to be given
one dose daily for 15 consecutive days. Administer directly on the
posteriodorsal surface of the mare's tongue using a dose syringe or suitable
plastic syringe. The drug may also be administered on the usual grain ration.
Dosage Schedule According To Mare's Approximate Weight:
770 lbs . . . 7 ml of Regu-Mate Solution
880 lbs . . . 8 ml
990 lbs . . . 9 ml
1100 lbs . . . 10 ml
1210 lbs . . . 11 ml
1320 lbs . . . 12 ml
Contraindications:
Regu-Mate (altrenogest) Solution 0.22% is
contraindicated for use in mares having a previous or current history of uterine
inflammation (i.e., acute, subacute, or chronic endometritis). Natural or
synthetic gestagen therapy may exacerbate existing low-grade or smoldering
uterine inflammation into a fulminating uterine infection in some instances.
Precautions:
Various synthetic progestins, including
altrenogest, when administer to rats during the embryogenic stage of pregnancy
at doses manyfold greater than the recommended equine dose caused fetal
anomalies, specifically masculinization of the female genitalia.
WHICH MARES WILL RESPOND TO REGU-MATE
(altrenogest) SOLUTION 0.22%: Extensive clinical trials
have demonstrated that estrus will be suppressed in approximately 95% of the
mares within three days; however, the post-treatment response depended on the
level of ovarian activity when treatment was initiated. Estrus in mares
exhibiting regular estrus cycles during the breeding season will be suppressed
during treatment; these mares return to estrus four to five days following
treatment and continue to cycle normally. Mares in winter anestrus with small
follicles continued in anestrus and failed to exhibit normal estrus following
withdrawal.
Response in mares in the transition phase
between winter anestrus and the summer breeding season depended on the degree of
follicular activity. Mares with inactive ovaries and small follicles failed to
respond with normal cycles post-treatment, whereas a higher proportion of mares
with ovarian follicles 20 mm or greater in diameter exhibited normal estrus
cycles post-treatment. Regu-Mate (altrenogest) Solution 0.22% was
very effective for suppressing the prolonged estrus behavior frequently observed
in mares during the transition period (February, March and April). In addition,
a high proportion of these mares responded with regular estrus cycles
post-treatment.
SPECIFIC USES FOR REGU-MATE (altrenogest)
SOLUTION 0.22%:
SUPPRESSION OF ESTRUS TO:
1. Facilitate attainment of regular cycles
during the transition period from winter anestrus to the physiological breeding
season.
To facilitate attainment of regular cycles
during the transition phase, mares should be examined to determine the degree of
ovarian activity. Estrus in mares with inactive ovaries (no follicles greater
than 20 mm in diameter) will be suppressed but these mares may not begin regular
cycles following treatment. However, mares with active ovaries (follicles
greater than 20 mm in diameter) frequently respond with regular post-treatment
estrus cycles.
2. Facilitate management of the mare exhibiting
prolonged estrus during the transition period. Estrus will be suppressed in
mares exhibiting prolonged behavioral estrus either early or late during the
transition period. Again, the post-treatment response depends on the level of
ovarian activity. The mares with greater ovarian activity initiate regular
cycles and conceive sooner than the inactive mares. Regu-Mate (altrenogest)
Solution 0.22% may be administered early in the transition period to suppress
estrus in mares with inactive ovaries to aid in the management of these mares or
to mares later in the transition period with active ovaries to prepare and
schedule the mare for breeding.
3. Permit scheduled breeding of mares during
the physiological breeding season. To permit scheduled breeding, mares which are
regularly cycling or which have active ovarian function should be given Regu-Mate
Solution 0.22% daily for 15 consecutive days beginning 20 days before the date
of the planned estrus.
Ovulation will occur 5 to 7 days following the
onset of estrus as expected for non-treated mares. Breeding should follow usual
procedures for mares in estrus. Mares may be regulated and scheduled either
individually or in groups.
Warning: Do not use in
horses intended for food.
Caution For Handlers:
Skin contact must be avoided as Regu-Mate
(altrenogest) Solution 0.22% is readily absorbed through unbroken skin.
Protective gloves must be worn by all persons handling this product. Pregnant
women or women who suspect they are pregnant should not handle Regu-Mate
(altrenogest) Solution 0.22%. Women of child bearing age should exercise
extreme caution when handling this product. Accidental absorption could lead to
a disruption of the menstrual cycle or prolongation of pregnancy. Direct contact
with the skin should therefore be avoided. Accidental spillage on the skin
should be washed off immediately with soap and water.
Regu-Mate (altrenogest)
Solution 0.22% is readily absorbed by the skin. Skin contact must be avoided;
protective gloves must be worn when handling this product.
Effects of Overexposure
There has been no human use of this specific
product. The information contained in this section is extrapolated from data
available on other products of the same pharmacological class that have been
used in humans. Effects anticipated are due to the progestational activity of
altrenogest.
Acute effects after a single exposure are
possible; however, continued daily exposure has the potential for more untoward
effects such as disruption of the menstrual cycle, uterine or abdominal
cramping, increased or decreased uterine bleeding, prolongation of pregnancy and
headaches. The oil base may also cause complications if swallowed.
In addition, the list of people who should not
handle this product (see below) is based upon the known effects of progestins
used in humans on a chronic basis.
People Who Should Not Handle This Product:
1. Women who are or suspect they are pregnant.
2. Anyone with thrombophlebitis or
thromboembolic disorders or with a history of these events.
3. Anyone with cerebral-vascular or
coronary-artery disease.
4. Women with known or suspected carcinoma of
the breast.
5. People with known or suspected
estrogen-dependent neoplasia.
6. Women with undiagnosed vaginal bleeding.
7. People with benign or malignant tumors which
developed during the use of oral contraceptives or other estrogen-containing
products.
8. Anyone with liver dysfunction or disease.
Accidental Exposure
Altrenogest is readily absorbed from contact
with the skin. In addition, this oil based product can penetrate porous gloves.
Altrenogest should not penetrate intact rubber or impervious gloves;
however, if there is leakage (i.e., pinhole, spillage, etc.), the contaminated
area covered by such occlusive materials may have increased absorption. The
following measures are recommended in case of accidental exposure.
Skin Exposure: Wash
immediately with soap and water.
Eye Exposure:
Immediately flush with plenty of water for 15 minutes. Get medical attention.
If Swallowed: Do not
induce vomiting. Regu-Mate (altrenogest) Solution 0.22% contains an
oil. Call a physician. Vomiting should be supervised by a physician because of
possible pulmonary damage via aspiration of the oil base. If possible bring the
container and labeling to the physician.
CAUTION: For oral use
in horses only. Keep this and all medication out of the reach of children.
Federal law
restricts this drug to use by or on the order of a licensed veterinarian
Store at room temperature.
Rx Medication Sold Only To Licensed Veterinarians & Pharmacies. Current License Must Be On File Prior To Shipping.
